The abstract is read at the publisher; the summary is JClub's.
Nirmatrelvir-ritonavir treatment in severe acute respiratory syndrome coronavirus 2–infected high-risk outpatients in Québec is linked to a 74% lower 30-day hospitalization risk (RR 0.26, 95% CI .23–.29).
- Why it matters: Evidence from the Omicron era is needed to confirm whether nirmatrelvir-ritonavir still reduces COVID-19-associated hospitalization among high-risk outpatients, including those with different vaccination statuses.
- What they did: In a retrospective Québec cohort (15 March–15 October 2022), propensity score matching compared 14 756 treated outpatients with untreated controls, and Poisson regression estimated 30-day relative risk.
- The result: The hospitalization RR was 0.13 (95% CI .08–.20; NNT 9) with an incomplete primary vaccination course and 0.28 (95% CI .25–.32; NNT 17) with a complete course; severely immunocompromised patients had RR 0.28 (95% CI .21–.36; NNT 7).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.